Clinical Trial Update: Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection [Phase 1]

View source ↗

Summary

Phase 1 exploratory study evaluating two investigational PI3K/mTOR inhibitors, XL765 (SAR245409) and XL147 (SAR245408), in patients with recurrent glioblastoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma

Drugs mentioned

• XL147 (SAR245408)
• XL765 (SAR245409)

Snippet

Sponsor: Sanofi | Conditions: Glioblastoma, Astrocytoma, Grade IV | Phase 1 | Status: COMPLETED